SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.

Slides:

Advertisements

Similar presentations

Ethnic differences in risks and explanations for the cardiometabolic syndrome in the UK Nish Chaturvedi Professor of Clinical Epidemiology Imperial College.

Advertisements

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

Pathophsiology of Metabolism. Obesity What Is Obesity? Obesity means having too much body fat.

High-density lipoprotein subclasses in subjects with impaired fasting glucose Filippatos TD 1, Barkas F 1, Klouras E 1, Liontos A 1, Rizos EC 1, Gazi I.

U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,

Factors associated with prediabetes in adult children of patients with premature coronary heart disease; the study of families of patients with premature.

Retinol Binding Protein-4 levels in thyroid overt and subclinical dysfunction Kokkinos Spiridon, Tiaka Elisavet, Manolakis Anastasios, Papanas Nikolaos,

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Cardiovascular Disease in Women Module III: Risk Assessment Tool.

Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.

Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,

Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

RISK FACTOR FOR CORONARY ARTERY DISEASE

Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.

AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.

1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.

1. Relation between dietary macronutrient and fiber intake with metabolic syndrome in Tehranian adults: Tehran Lipid and Glucose Study Hosseinpour S,

Blood pressure control in primary health care WORKSHOP

Conclusion In conclusion, preliminary data from this nutrition intervention study suggest that a well balanced Mediterranean-type diet is able to reduce.

Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.

Sense of coherence and carotid artery intima media thickness measurements: presenting four case reports from the Spili cohort in rural Crete, Greece D.

BASIC analysis of --- Stress/overwork and cardiovascular disease data Sino-Japanese cooperation project by Mile Xiu.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Diabetes National Diabetes Control Programme

Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.

High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

The Relation of Interleukin 6 Gene-190 T/C Polymorphisms with Anthropometric and Biochemical Characteristics in a group of Obese Children Authors: Mărginean.

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.

Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.

Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.

Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.

Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.

The short term effects of metabolic syndrome and its components on all-cause-cause mortality-the Taipei Elderly Health Examination Cohort Wen-Liang Liu.

DOES LEPTIN LEVELS AFFECT CARDIOMETABOLIC FACTORS INDEPENDENTLY OF ADIPOSITY IN OBESE BRAZILIAN CHILDREN? Maria Edna Melo 1,2,3, Clarissa TH Fujiwara 1,

PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.

Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients Giovanni Targher, Lorenzo Bertolini, Felice Poli,

Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,

From ESH 2016 | LB 3: Davide Agnoletti, MD

*Imperial College London

Baseline characteristics and effectiveness results

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Elevated Circulating Levels of Inflammatory Markers in

Insulin resistance in prepubertal children

Copyright © 2007 American Medical Association. All rights reserved.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

HDL cholesterol and cardiovascular risk Epidemiological evidence

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

The Hypertension in the Very Elderly Trial (HYVET)

The results of the SHARP trial

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Type 2 diabetes: Overlap of clinical conditions

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Dr Stephanie Jones, Dr Amal Khanolkar, Dr Krystyna Matyka,

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.

Level of risk factor control in the overall sample and by gender

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Baseline Characteristics of the Subjects*

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

The results of the SHARP trial

PROSPER: trial design

Presentation transcript:

SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos 1, M. Georgoula 1, Z. Mitrogianni 1, AD Tselepis 2, MS Elisaf 1 1Department of Internal Medicine, School of Medici1ne, University of Ioannina, Ioannina, Greece 2Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece

Background  Human visfatin has been implicated in the pathogenesis of type 2 diabetes mellitus, obesity, dyslipidaemia, and hypertension and generally of atherosclerosis-related diseases.  Controversial results exist regarding the expression, circulating levels and the role of visfatin in the atherosclerosis-related diseases.

Aim of the study Aim of the present study was to assess in non-diabetic individuals the association of plasma visfatin levels with cardiovascular disease (CVD) risk and the atherosclerosis - related metabolic variables.

Methods (1)  Non-diabetic subjects (n = 179) attending the Outpatient Lipid Clinic of the University Hospital of Ioannina participated in the present study.  No participant had symptomatic ischemic heart disease or any other clinically evident vascular disease (assessed by history, physical examination, electrocardiogram and routine biochemical check). Exclusion criteria  Symptomatic ischemic heart disease or any other clinically evident vascular disease  Abnormal hepatic function (aminotransferase activity > 3 times the upper limit of normal, and/or history of chronic liver disease, such as cirrhosis or alcoholic liver disease)  Impaired renal function (serum creatinine levels > 159 μmol/L, 1.8 mg/dL)  Raised thyroid-stimulating hormone (TSH) levels (> 5.0 μU/L)  Drugs that may interfere with glucose or lipid metabolism.

Results (1) Baseline demographic characteristics of study patients N (females/males)179 (107/72) Age, years49 ± 11 (range 27 – 78) Current smokers, %22.3 Body weight, kg82 ± 18 BMI, kg/m ± 7.7 Waist circumference, cm101 ± 15 Diastolic BP, mm Hg84 ± 10 Systolic BP, mm Hg132 ± 18 Visfatin, ng/ml Tertile (7.0 – 16.0) Tertile (16.2 – 23.0) Tertile (23.6 – 57.0) BMI = body mass index; BP = blood pressure Values are expressed as mean ± SD, except visfatin which is expressed as median (range).

Results (2) Ten-year Framingham risk scores for coronary heart disease (CHD), myocardial infarction (MI), stroke and cardiovascular disease (CVD) according to visfatin tertiles Parameter Tertile 1 N = 61 Tertile 2 N = 59 Tertile 3 N = 59 p (ANOVA) CHD (%) a 0.02 MI (%) a 0.04 STROKE (%) NS CVD (%) a 13.0 a 0.007

Results (3) Anthropometric variables according to visfatin tertiles BMI = body mass index a = p < 0.05 vs tertile 1 (post-hoc analysis) b = p < 0.05 vs tertile 2 (post-hoc analysis) Visfatin tertiles

Results (4) Blood pressure according to visfatin tertiles SBP = systolic blood pressure; DBP = diastolic blood pressure a = p < 0.05 vs tertile 1 (post-hoc analysis) Visfatin tertiles

Results (5) Metabolic variables according to visfatin tertiles Visfatin tertiles

Results (6) Anthropometric and biochemical variables according to visfatin tertiles Parameter Tertiles p (ANOVA or χ 2 ) Age (years)47 ± 11 (29 -73)50 ± 11 (27 -78)51 ± 12 (29 -74)NS Gender (females/males) 34/2740/1933/26NS HOMA index1.9 (0.4 – 12.0)2.8 (0.9 – 18.2) a 2.6 (0.9 – 19.8) a 0.01 Uric acid (mg/dl)4.8 ± ± ± 1.5 a 0.03 apoE (mg/L)33 ± 1538 ± 1445 ± 27 a 0.01 Lp(a) (mg/L)8.9 (0 -73)10.5 (0 – 113) a 10.5 (0 – 102) a 0.04

Results (7) LDL subclasses according to visfatin tertiles

Results (8) HDL subclasses according to visfatin tertiles

Conclusions Our results support a role for visfatin in the detection of subjects with many metabolic abnormalities, which result in an increased CVD risk.